Amazon ( AMZN) upgraded at Pipier Jaffray to Buy from Neutral based on strong customer satisfaction in recent survey. Expect market share gains and continued ecommerce innovations such as the Kindle. Price target raised to $81 from $55. Banco Bradesco ( BBD) downgraded at Goldman Sachs to Sell from Neutral based on limited excess reserves and recent outperformance vs. ITU. See limited upside as investors focus on book value metrics. Price target cut to $8.50 from $9.80. Best Buy ( BBY) upgraded at William Blair from Market Perform to Outperform. Company will emerge from the recession in a much stronger position. Genentech ( DNA) target cut Morgan Stanley to $97. Expect Roche deal to happen, but at a higher price. Overweight rating. Genentech ( DNA) downgraded at Jefferies from Buy to Hold. $93 price target. Expect Roche's latest offer to be successful. Genzyme ( GENZ) upgraded at Deutsche Bank from Hold to Buy. $63 price target. Stock offers growth at a reasonable price. Int'l. Game Technologies ( IGT) downgraded at Goldman to Neutral from Buy based on mediocre showing in slot managers survey that indicates company is losing market share to WMS. Believe turnaround will take time and note refinancing risk. Price target cut to $9 from $14. Intrepid Potash ( IPI) upgraded at Oppenheimer to Outperform. $20 price target. Valuation call, as the company will benefit from long-term demand growth. Coca-Cola ( KO) upgraded at Credit Suisse to Outperform from Neutral based on valuation and fundamental strength of local operations in key markets outside the U.S. Raised target price to $48 from $47.